Related references
Note: Only part of the references are listed.Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A. Argiris et al.
ANNALS OF ONCOLOGY (2013)
Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
Takayuki Yoshino et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
Christopher R. Flowers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Barbara Burtness et al.
LANCET ONCOLOGY (2013)
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer
Joseph I. Clark et al.
MEDICAL ONCOLOGY (2013)
Treatment of Cancer-Associated Anaemia: Results from a Two-Day Cross-Sectional Survey in Germany
Hartmut Link et al.
ONKOLOGIE (2013)
Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
Luigi Celio et al.
PATIENT PREFERENCE AND ADHERENCE (2013)
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
R. Hitt et al.
ANNALS OF ONCOLOGY (2012)
Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices
Ramon Andrade De Mello et al.
CLINICS (2012)
Association between EGF+61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study
Ramon Andrade de Mello et al.
TUMOR BIOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Alison G. Freifeld et al.
CLINICAL INFECTIOUS DISEASES (2011)
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE
Steven Grunberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Association between EGF+61A/G polymorphism and gastric cancer in Caucasians
Ana Paula Araujo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies
Ramon Andrade de Mello et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2011)
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
R. Mesia et al.
ANNALS OF ONCOLOGY (2010)
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
V. Gregoire et al.
ANNALS OF ONCOLOGY (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens
Elena Massa et al.
ORAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Ezra E. W. Cohen et al.
LANCET ONCOLOGY (2009)
Drug therapy: Chemotherapy-induced nausea and vomiting
Paul J. Hesketh
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Association between functional EGF+61 polymorphism and glioma risk
Bruno Marques Costa et al.
CLINICAL CANCER RESEARCH (2007)
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Ezra E. W. Cohen
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment
R Haddad et al.
ONCOLOGIST (2003)
Association between functional polymorphism in EGF gene and malignant melanoma
M Shahbazi et al.
LANCET (2002)
Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: When do the ends justify the means?
WJ Goodwin
LARYNGOSCOPE (2000)
Share Paper
